Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4B deal

By Reuters
| August 10, 2022

(Reuters) - Pfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics, as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment.

Full story

#1

Recent research on Paxlovid shows there is "solid data on its effectiveness," a co-author of the study told HealthLeaders. ...

A new personal protective equipment manufacturing company is set to open in Cincinnati next year. ...